Aleniglipron
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Gasherbrum Bio, Inc · Phase 3 · Recruiting · Enrollment 3600
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| aleniglipron Arm 1 | n/r | n/r | n/r | n/r |
| aleniglipron Arm 2 | n/r | n/r | n/r | n/r |
| aleniglipron Arm 3 | n/r | n/r | n/r | n/r |
| Placebo Arm 4 | n/r | n/r | n/r | n/r |
Not shown
- aleniglipron Arm 1: endpoint not reported
- aleniglipron Arm 2: endpoint not reported
- aleniglipron Arm 3: endpoint not reported
- Placebo Arm 4: endpoint not reported